Belite Bio Inc ADR(BLTE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:00 PM ET (Korea 10/29 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.73 | Insider Own | 1.8% | Shs Outstand | 40.3M | Perf Week | -2.91% |
| Market Cap | 5.99B | Forward P/E | 78.27 | EPS next Y | 159.75% | Insider Trans | -21.43% | Shs Float | 39.5M | Perf Month | -10.76% |
| Enterprise Value | 5.71B | PEG | - | EPS next Q | -0.79 | Inst Own | 22.24% | Short Float | 3.2% | Perf Quarter | -7% |
| Income | -0.10B | P/S | - | EPS this Y | -37.66% | Inst Trans | 0.72% | Short Ratio | 6.99 | Perf Half Y | -3.74% |
| Sales | 0.00B | P/B | 7.71 | EPS next 5Y | - | ROA | -21.6% | Short Interest | 1.27M | Perf YTD | -7.03% |
| Book/sh | 19.28 | P/C | 21.4 | EPS past 3/5Y | -54.04% -549.64% | ROE | -22.1% | 52W High | -25.64% ($200.00) | Perf Year | 59.88% |
| Cash/sh | 6.95 | P/FCF | - | Sales past 3/5Y | - | ROIC | -13.28% | 52W Low | 63.85% ($90.76) | Perf 3Y | 299.25% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -76.46% | Gross Margin | - | Volatility(W/M) | 3.51% 3.82% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 6.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 50.02 | EPS Q/Q | -41.19% | Profit Margin | - | RSI (14) | 43.17 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 50.02 | Sales Q/Q | - | SMA20 | -2.46% ($152.47) | Beta | -1.23 | Target Price | $228.89 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -8.19% ($161.99) | Rel Volume | 0.45 | Prev Close | $145.72 |
| Employees | 41 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 9.89% - | SMA200 | -7.28% ($160.4) | Avg Volume(3M) | 0.18M | Price | $148.72 |
| IPO | 2022/4/29 | Option/Short | Yes/Yes | Trades | 1568 | Volume | 81,865 | Change | 2.06% |
This is an American Depositary Receipt (ADR) for a clinical-stage biotech company developing retinal disease treatments. It focuses on late-stage clinical development of oral therapy candidates targeting inherited retinal diseases and age-related macular degeneration. As a biohealthcare stock, its price is driven by clinical results, regulatory filings, and funding conditions related to its lead candidate.
Over the past 1 year, roughly in the middle
26% below its 1-year high.
Traded less than usual. That is 45% of its average volume.
BLTE has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -37.7% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be +299.3%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 22.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #46 of 594 in the industry
Based on market cap of $6B.
KOD#43 Kodiak Sciences Inc $6B PER - 
IMVT#44 Immunovant Inc $6B PER - 
MANE#45 Veradermics Inc $6B PER - BLTE#46 Belite Bio Inc ADR $6B PER - 
CGON#47 Cg Oncology Inc $6B PER - 
FAQ
What kind of company is BLTE?
BLTE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BLTE?
The market cap of BLTE is approximately $6.0B, ranking 1,233 within its sector.
What is the 52-week high and low for BLTE?
BLTE has recorded a 52-week high of $200.00 and a low of $90.76.
